KQB365 + cetuximab

KQB365 + cetuximab is a combination therapy under investigation for the treatment of advanced solid malignancies, specifically including colorectal cancers with KRAS G12C or G12S mutations. KQB365 is an investigational agent, likely a small molecule or biologic, developed for its anti-tumor properties and may act by modulating the expression of tumor suppressor genes such as KLF4 and disrupting key oncogenic signaling pathways involved in tumor growth and survival. Cetuximab is a well-established monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting downstream proliferative signaling. Together, this combination seeks to enhance anti-tumor effects in KRAS-mutated cancers that are otherwise not amenable to curative treatment. The regimen is administered as weekly intravenous infusions, with clinical trials currently evaluating its safety, tolerability, pharmacokinetics, and preliminary efficacy in relevant patient populations[2][3][5][9].